Last reviewed · How we verify
Carboplatinum and Taxol
Carboplatinum and Taxol is a Small molecule drug developed by Gradalis, Inc.. It is currently in Phase 2 development.
At a glance
| Generic name | Carboplatinum and Taxol |
|---|---|
| Sponsor | Gradalis, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial (PHASE2)
- Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer (PHASE3)
- Reduced-dose Carboplatin-doublet-chemotherapy + Cemiplimab vs Cemiplimab Monotherapy in Treatment Naive Older and Frail Patients With Metastatic NSCLC With PD-L1 <50% (PHASE2)
- A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011) (PHASE3)
- A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) (PHASE3)
- Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer (PHASE2)
- Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer (PHASE3)
- Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023] (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Carboplatinum and Taxol CI brief — competitive landscape report
- Carboplatinum and Taxol updates RSS · CI watch RSS
- Gradalis, Inc. portfolio CI
Frequently asked questions about Carboplatinum and Taxol
What is Carboplatinum and Taxol?
Carboplatinum and Taxol is a Small molecule drug developed by Gradalis, Inc..
Who makes Carboplatinum and Taxol?
Carboplatinum and Taxol is developed by Gradalis, Inc. (see full Gradalis, Inc. pipeline at /company/gradalis-inc).
What development phase is Carboplatinum and Taxol in?
Carboplatinum and Taxol is in Phase 2.
Related
- Manufacturer: Gradalis, Inc. — full pipeline
- Compare: Carboplatinum and Taxol vs similar drugs
- Pricing: Carboplatinum and Taxol cost, discount & access